Product Description: Citalopram-d3 hydrochloride is deuterated labeled Citalopram (HY-121203). Citalopram is a racemate mixture of the active S(+)-enantiomer (Escitalopram; HY-14258) and R(-)-enantiomer. Citalopram is an orally active selective serotonin reuptake inhibitor (SSRI). Citalopram is an antidepressant and enhances serotoninergic neurotransmission[1][2][3].
Applications: Cancer-programmed cell death
Formula: C20H19D3ClFN2O
References: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216./[2]Carlsson B, et al. Enantioselective analysis of citalopram and escitalopram in postmortem blood together with genotyping for CYP2D6 and CYP2C19. J Anal Toxicol. 2009;33(2):65-76. /[3]Laurent Sakka, et al. Assessment of citalopram and escitalopram on neuroblastoma cell lines. Cell toxicity and gene modulation. Oncotarget. 2017 Jun 27;8(26):42789-42807./[4]Milne RJ, et al. Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs. 1991;41(3):450-477. /[5]Zeng-Liang Jin, et al. Mouse strain differences in SSRI sensitivity correlate with serotonin transporter binding and function. Sci Rep. 2017 Aug 17;7(1):8631.
Molecular Weight: 363.87
Research Area: Cancer; Neurological Disease
Solubility: 10 mM in DMSO
Target: Isotope-Labeled Compounds;Serotonin Transporter
English
Deutsch
